{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Loughman J"],"pubmed_abstract":["<h4>Purpose</h4>To investigate the safety, tolerability, and signals of effect of MyopiaX, a smartphone app that selectively delivers blue light to the optic nerve head to control myopia progression in children and adolescents.<h4>Design</h4>Multicenter, randomized, active-controlled, examiner-masked proof-of-concept clinical trial (ClinicalTrials.gov identifier NCT04967287).<h4>Participants</h4>Eligible children aged 6 to 12 years, with myopia of cycloplegic spherical equivalent refraction (SER) between -0.75 and -5.00 diopters (D) at baseline. Children were screened and enrolled between November 2021 and September 2023.<h4>Methods</h4>Children were randomly assigned in a 2:1 ratio to MyopiaX or active control. Participants were instructed to use MyopiaX for 10 minutes twice daily for the"],"journal":["Ophthalmology science"],"pagination":["100973"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12719902"],"repository":["biostudies-literature"],"pubmed_title":["MyopiaX-1 Safety and Efficacy of a Novel Approach to Slow Juvenile Myopia Progression: A Multicenter, Randomized, Controlled Trial."],"pmcid":["PMC12719902"],"pubmed_authors":["Kaymak H","Morales Ballus M","Batres L","Gosheva M","Fernandes PR","Mattern AI","Silva-Leite S","Klaver C","Polling JR","Porras Angel P","Deuter C","Pastrana Robles C","Peters T","Dahlmann-Noor AH","MyopiaX-1 Study Group","Flitcroft I","Bodas Romero J","Lingham G","Amorim-de-Sousa A","Peixoto-de-Matos SC","Carpena Torres C","Muller PL","Serramito Blanco M","Ganan EJ","Gonzalez-Meijome JM","Devenijn M","Katona T","Carracedo G","Folga R","Beck A","Lorenz K","Arroyo Del Arroyo C","Loughman J","Neller B","Liman K"],"additional_accession":[]},"is_claimable":false,"name":"MyopiaX-1 Safety and Efficacy of a Novel Approach to Slow Juvenile Myopia Progression: A Multicenter, Randomized, Controlled Trial.","description":"<h4>Purpose</h4>To investigate the safety, tolerability, and signals of effect of MyopiaX, a smartphone app that selectively delivers blue light to the optic nerve head to control myopia progression in children and adolescents.<h4>Design</h4>Multicenter, randomized, active-controlled, examiner-masked proof-of-concept clinical trial (ClinicalTrials.gov identifier NCT04967287).<h4>Participants</h4>Eligible children aged 6 to 12 years, with myopia of cycloplegic spherical equivalent refraction (SER) between -0.75 and -5.00 diopters (D) at baseline. Children were screened and enrolled between November 2021 and September 2023.<h4>Methods</h4>Children were randomly assigned in a 2:1 ratio to MyopiaX or active control. Participants were instructed to use MyopiaX for 10 minutes twice daily for the","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-08T05:26:54.952Z","creation":"2026-06-08T03:08:36.572Z"},"accession":"S-EPMC12719902","cross_references":{"pubmed":["41438818"],"doi":["10.1016/j.xops.2025.100973"]}}